Attending the #AACR24 AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology Award Lecture, by Gordon Freeman? Read his work identifying KIR3DL3 as an inhibitory receptor for HHLA2. https://t.co/pFx2JizM2C @alyssa_klee https://t.co/gSO8UBCf
If you are checking in on #AACR21 ‘Mapping the Cellular and Molecular Cues that Control Therapeutic Antitumor Immunity,’ you may be interested in these @CIR_ACCR papers! Enjoy! 😃🤓#KIR3DL3 #PD1 #IDO1 #IFN #HHLA2 #ICB https://t.co/tacgSAROqN https://t.co/GO
ICYMI: Check out #HHLA2, a ligand for #KIR3DL3, and how its targeting is a potential immunotherapeutic! #PD1 #NKcells @alyssa_klee https://t.co/l6o77nrUQA https://t.co/GWiZhaxlFJ
Learn how targeting #HHLA2, a ligand for #KIR3DL3, is a potential immunotherapeutic: #PD1 #NKcells @alyssa_klee https://t.co/HuOxgOLrhi https://t.co/uXBmEj8YMe
Sharing for collaboration on #RCC research. The work results approximates figuring out your opponent’s likely hand in poker.
RT @LabWaggoner: KIR3DL3 is inhibitory R for HHLA2 in T and NK cells. HHLA2 expression was non-overlapping with PDL1 expression in cell ren…
RT @LabWaggoner: KIR3DL3 is inhibitory R for HHLA2 in T and NK cells. HHLA2 expression was non-overlapping with PDL1 expression in cell ren…
RT @LabWaggoner: KIR3DL3 is inhibitory R for HHLA2 in T and NK cells. HHLA2 expression was non-overlapping with PDL1 expression in cell ren…
RT @LabWaggoner: KIR3DL3 is inhibitory R for HHLA2 in T and NK cells. HHLA2 expression was non-overlapping with PDL1 expression in cell ren…
KIR3DL3 is inhibitory R for HHLA2 in T and NK cells. HHLA2 expression was non-overlapping with PDL1 expression in cell renal cell carcinoma, suggesting HHLA2 mediates tumor immune evasion independent from PDL1. https://t.co/WbDNIsPHpt
RT @romeerizwan: Great work from Freeman lab @DanaFarber https://t.co/tgiAjHrE8h
RT @romeerizwan: Great work from Freeman lab @DanaFarber https://t.co/tgiAjHrE8h
Great work from Freeman lab @DanaFarber https://t.co/tgiAjHrE8h
KIR3DL3 is an inhibitory receptor for HHLA2 that mediates an alternative immunoinhibitory pathway to PD1. by Bhatt RS, Berjis A, Konge JC, Mahoney KM, Klee AN, Freeman SS, Chen CH, Jegede OA, Catalano PJ, Pignon JC, Sticco-Ivins M, Zhu B, Hua P, Soden J…